CD38 and prostate neoplasm: CD38, a druggable ectoenzyme, has been shown to be expressed on diverse prostate tumor-infiltrating immune cells (TIICs), and the CD38+ TIIC density is independently related to worse overall survival of patients with PC (Guo et al., 2021).